Generation of Human Hepatocytes

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2004
Program:
STTR
Phase:
Phase I
Contract:
1R41DK067786-01
Agency Tracking Number:
DK067786
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
IN VIVO TECHNOLOGIES
IN VIVO TECHNOLOGIES, 1121 FOREST ST, RENO, NV, 89509
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ESMAIL ZANJANI
(775) 328-1232
ZANJANI@SCS.UNR.EDU
Business Contact:
(775) 322-5889
Research Institution:
SIERRA BIOMEDICAL RESEARCH CORPORATION

SIERRA BIOMEDICAL RESEARCH CORP
RENO, NV, 89502

Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Transplantation of human bone marrow (BM) CD34+ cells from normal donors of diverse genetic background into pre-immune fetal sheep/pigs can be used to generate human liver cells for use in drug toxicity studies (the aim of the present application), and from specific patients to produce livers and/or cells autologous to the patient (future goal requiring proof-of-principle studies). Feasibility data is presented demonstrating that the transplantation of CD34+ cells from human BM, mobilized peripheral blood, and cord blood into this non-injury pre-immune fetal sheep model resulted in the robust formation of relatively large numbers of human liver cells that synthesize and secret human albumin into circulation. In this human/sheep xenograft model donor (human) hepatopoiesis persists long-term (> 2years) without apparent loss of number or function. In the phase I effort we propose to determine: 1) the optimal gestational age of the sheep fetus, and 2) the optimal concentration of human bone marrow CD34+ cells for obtaining the highest percentages of human hepatocytes. Phase II effort will focus on efficient isolation, characterization, and maintenance of human liver cells from the "humanized" liver.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government